(Q36788591)

16 August 2017

1 reference

title

Improving the efficacy of trastuzumab in breast cancer (English)

1 reference

16 August 2017

1 reference

2

Masakazu Toi

1 reference

16 August 2017

Eiji Suzuki

1

1 reference

16 August 2017

publication date

12 April 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

98

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

767-771

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Clinical applications of anti-CD20 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Issues and progress with protein kinase inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00455.X

10.1111/J.1349-7006.2007.00455.X

21 January 2018

Identifiers

DOI

1 reference

release_emh72ha62bcbtfstcmz7eychli

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/emh72ha62bcbtfstcmz7eychli

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference